The End of the Rebate Era? Employers Push for Transparency in Pharmacy Benefit Management

As the American healthcare landscape grapples with soaring prescription drug costs, a significant shift is occurring in the corporate boardroom. A growing cohort of U.S. employers, responsible for providing health coverage to millions of workers, is signaling a definitive departure from the traditional Pharmacy Benefit Manager (PBM) compensation model. According to a recent survey conducted for Evernorth, an overwhelming majority of large employers are now advocating for a rebate-free approach, citing a desperate need for transparency, simplicity, and predictable budgeting.

The survey, which polled 300 employers with at least 1,000 employees, found that more than 90% of respondents believe a rebate-free pharmacy model is inherently easier to understand. Furthermore, 86% of those surveyed noted that removing rebates from the equation would significantly improve the predictability of pharmacy spending—a perennial pain point for human resources departments managing volatile healthcare budgets.

The Role of PBMs in the Drug Supply Chain

To understand the magnitude of this shift, one must first understand the role of the PBM. Acting as the critical intermediaries between pharmaceutical manufacturers, health insurance plans, and pharmacies, PBMs wield immense power. They are responsible for negotiating rebates from drugmakers, developing medication formularies (the list of covered drugs), and managing pharmacy networks.

For decades, the standard PBM model relied on the "rebate" system. In this arrangement, PBMs negotiate discounts with manufacturers in exchange for preferred placement on a formulary. Critics, however, have long argued that this system creates perverse incentives. Because PBMs often retain a percentage of these rebates, they are financially incentivized to favor high-list-price drugs over cheaper, equally effective alternatives—a practice that critics claim has fueled the rapid inflation of medication costs.

Chronology of a Regulatory and Market Shift

The move toward a rebate-free model did not happen in a vacuum. It is the result of years of mounting political pressure, litigation, and a changing market environment.

• 2024 – The FTC Takes Action: The Federal Trade Commission (FTC) filed a landmark lawsuit against the "Big Three" PBMs—UnitedHealth’s Optum Rx, CVS Caremark, and Cigna’s Express Scripts. The federal regulator alleged that these entities engaged in anti-competitive practices by steering patients toward more expensive insulin products to maximize their own rebate revenues.
• Late 2024 – Express Scripts Pivots: In response to shifting market expectations and legal scrutiny, Express Scripts announced it would begin transitioning toward a rebate-free, cost-plus model.
• Early 2025 – Legislative Reform: President Donald Trump signed a significant funding bill into law, which included critical PBM reforms. These provisions mandated new transparency requirements and prohibited PBMs from linking their compensation to manufacturers’ list prices within Medicare Part D.
• Early 2026 – Settlement and Standardization: Express Scripts reached a formal settlement with the FTC, agreeing to end the practice of preferring drugs based on high list prices and committing to delink compensation from negotiated manufacturer savings.
• May 2026 – Industry-Wide Adoption: Following the trend, Optum Rx announced on May 11, 2026, that it would shift to a fee-based pharmacy benefits model, decoupling client costs from manufacturer list prices and prescription volume.

Supporting Data: Why Employers are Changing Course

The data from the Evernorth survey highlights a clear consensus among corporate benefits leaders. Beyond the 90% who favor simplicity, the survey revealed that 87% of employers believe a rebate-free structure better aligns with their organization’s long-term health goals.

The financial volatility inherent in the current rebate model has left many companies struggling to forecast year-over-year healthcare expenses. By moving to a flat-fee or cost-plus model, employers gain "predictability"—a metric that allows for more accurate budgeting and potentially lower premiums for employees. When the PBM’s profit is no longer tethered to the list price of the drug, the incentive to push expensive therapies evaporates, theoretically opening the door for a more cost-effective formulary.

Official Responses and Strategic Shifts

The industry leaders themselves have acknowledged that the "old way" of doing business is no longer sustainable.

Ashley Holzworth-Nash, Vice President of Retail Network Product Strategy and Solutions at Evernorth, summarized the sentiment during a recent briefing: "This data confirms employers want pharmacy benefits that are easier to understand, easier to budget for, and designed around the experience of the people they cover."

The shift at Optum Rx, the nation’s largest PBM, is perhaps the most significant indicator of this structural change. By moving to a model where clients pay a transparent monthly fee, Optum is effectively dismantling the "black box" of PBM pricing. Under this new structure, there is no ambiguity regarding where the money goes. The pharmacy benefit is treated more as a service—managing drug access and clinical outcomes—rather than a revenue-generation vehicle based on drug price inflation.

Implications for the Future of Healthcare

The implications of a shift away from rebates are profound, affecting every stakeholder in the pharmaceutical ecosystem.

1. For Employers and Employees

For the employer, the shift promises cost containment. For employees, the promise is improved access to medications that are chosen for their clinical efficacy rather than their rebate potential. If the "rebate-chasing" behavior is removed, patients may find that their co-pays are no longer inflated by the high list prices of preferred drugs.

2. For Pharmaceutical Manufacturers

Manufacturers may face a new reality where they can no longer "buy" market share through high rebates. This could force a pivot back to innovation-based competition, where drugmakers compete on price and patient outcomes rather than their ability to offer the largest kickbacks to PBMs.

3. For the PBM Industry

The era of the "middleman" is undergoing a forced evolution. PBMs will likely remain essential for their administrative and logistical capabilities, but their business model is being forced into the light. Future revenue will likely come from administrative service fees, transparent management, and the proven ability to improve health outcomes, rather than the opaque manipulation of drug pricing.

4. Regulatory Outlook

While the FTC’s lawsuits and the recent federal funding bill have acted as catalysts, the work is far from finished. Legislators continue to watch the industry closely, and should the move toward transparency stall, further regulatory intervention is likely. The current "voluntary" shift by major players like Express Scripts and Optum Rx is a strategic move to preempt more draconian federal mandates.

Conclusion

The findings from the Evernorth-commissioned survey serve as a bellwether for the pharmacy benefits industry. Employers have reached a breaking point, demanding a level of transparency that was, until recently, considered impossible to achieve. As the industry transitions toward fee-based, rebate-free models, the focus of pharmacy management is finally realigning with its original purpose: providing affordable, high-quality medication access to the American workforce. Whether this transition will be enough to curb the long-term trend of rising drug costs remains to be seen, but for the first time in decades, the incentive structures are beginning to move in the right direction.